Durham biotech Ribometrix raises $7.8M
DURHAM, N.C. – Ribometrix, a four-year-old startup focused on the use of ribonucleic acid, a nucleic acid present in all cells known as RNA, to target disease, has closed on another $7.8 million in venture funding. Previous investors Dementia Discovery Fund and Illumina Ventures participated in the round. Last November, Ribometrix raised $30 million. The firm also named Mike Claymann, an MD, as chair of the board. Clayman co-founded Flexion Therapeutics in 2007 and has since served as its president and CEO, Hatteras Venture Partners and Pappas Capital are among the firm’s earlier...
Read MoreCorporate Venture Capital Panel Announced!
The Southeast BIO Investor & Partnering Forum is honored to be able to present a panel of distinguished corporate venture capitalists on its opening day, Wednesday, November 6, in Coral Gables, Florida at the Biltmore Hotel. These panelists will provide insight into how to work with corporations, the largest source of capital for biopharma companies. Our panelists will be John Gustofson of AbbVie Ventures, who will double as moderator, Gladys Nunez of Amgen, Diana Bernstein of MRL Ventures Fund and Akhil Saklecha of Cleveland Clinic Ventures. John Gustofson, Managing Director, AbbVie...
Read MoreEarly Bird Ends October 5th!!
Save $100 by registering by Saturday, October 5th!! New conference format! Great speakers lined up! Join us in Miami November 6-7.
Read MoreZielBio Closes $25.1 Million Series A Financing
CHARLOTTESVILLE, VA. – ZielBio, Inc., an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes, has closed a $25.1 million Series A financing round. The round is led by Morningside Venture Investments and Partners Innovation Fund (PIF). ZielBio’s lead candidate ZB131 is a proprietary humanized monoclonal antibody against cell surface plectin (CSP), a target that is highly expressed on the plasma membrane of multiple types of cancer cells, including ovarian, pancreatic, lung and colorectal....
Read MoreAntios Therapeutics’ Record-Breaking Year
Please join us on Thursday, November 7, at 8:30 AM at the 21st Annual Southeast BIO Investor & Partnering Forum for breakfast and a fireside chat on building game-changing companies in the field of antiviral medicine, creativity in drug discovery, and novel models of academia-industry collaboration. Dr. Abel De La Rosa, CEO of Atlanta-based Antios Therapeutics and Gerry Brunk, Managing Director of Lumira Ventures, will hold a fireside chat to discuss the founding story of Antios, the role of creative thinking in the discovery of new drugs and lessons learned from building...
Read MoreVivex Biomedical’s Success Story Explored
Vivex Biomedical’s Success Story Explored Please join us on Thursday, November 7, at 3:00 PM at the 21st Annual Southeast BIO Investor & Partnering Forum for a fire-side chat on the emergence, funding, and growth of Vivex Biomedical with “Vivex Biomedical: Tissue-Derived Biologic Therapies.” Tom Callaway, venture partner at HealthQuest Capital, will interview the senior leadership that built this Fort Lauderdale-based success. Panelists will include Vivex Founder Tracy S. Anderson who is an Atlanta-based serial entrepreneur, John A. McCallum of private...
Read More
Follow Us!